Expanding Horizons in Multiple Myeloma

Welcome to a dedicated resource to help you find the latest information on Multiple Myeloma (MM), measuring treatment response and research into new classes of treatment.

What is Multiple Myeloma?

Explore the foundations of MM, including disease pathogenesis, epidemiology, diagnostic methods and measuring treatment response.

Strengthen Expertise in Multiple Myeloma

Recent treatment advances offer new options for patients with MM. Find out more about current treatment options, as well as upcoming novel therapies.

What is Multiple Myeloma?

About Multiple Myeloma

Despite significant treatment advances, MM remains an incurable and challenging disease. Find out more about the evolution of MM.

Focusing on Diagnosis

Early diagnosis is critical in MM.1 An array of diagnostic methods can be used to characterise a patient’s MM, allowing for individualised treatment and management.

Response measurements

The right treatment plan can improve a patient treatment response. Find out how treatment response is measured and what strides are being taken to optimise it.

Strengthen your expertise

Treating Multiple Myeloma

Treatment aims to extend survival by stopping or slowing down growth and spread of myeloma cells. In addition, therapy can alleviate patients’ symptoms and complications, and improve quality of life.

Emerging Targets
Despite substantial treatment progress, MM remains an incurable disease. Emerging therapeutics, including those with novel mechanisms of action, are offering new options for patients with MM.[1]

Janssens heritage in Multiple Myeloma

At Janssen, we have more than 30 years of innovation in oncology. Collaborations with Millennium Pharmaceuticals/Takeda Oncology and Genmab have allowed us to co-develop and commercialise a proteasome inhibitor bortezomib (co-developed by Millennium/Takeda and Janssen), and an anti-CD38 monoclonal antibody (mAb) daratumumab (co-developed by Genmab and Janssen). These products have helped to improve the lives of thousands of patients. We continue our commitment to research and development of new treatments and believe that collaboration with external partners is key to advancing patient care.

As the Multiple Myeloma treatment landscape is rapidly evolving, continuous education is paramount. At Janssen, we are committed to delivering high-quality medical education built on a platform of knowledge exchange and innovation. To help achieve this, we are privileged to have the support and participation of the internationally renowned experts who form our scientific committees and faculties. Their involvement ensures that we continue to provide clinically relevant and balanced education.


The HME-Forum is an innovative online forum for haematologists, developed by an eminent scientific committee. Through live interactive broadcasts, clinicians can learn from experts as they discuss the latest data and its impact on clinical practice.

Clinical Trials

Several clinical trials have recently been completed for MM treatments. Additionally, numerous early preclinical and clinical trials with new drug targets are ongoing.

EM-64626 - November 2021